Abstract 51P
Background
Conversion therapy for biliary tract cancer has attracted increasing interest in recent years. Camrelizumab plus oxaliplatin-based chemotherapy has shown clinical activity as the first-line treatment for patients (pts) with advanced BTC. HAIC with oxaliplatin and 5-fluorouracil (HAIC-FO) could improve the objective response rate (ORR) in advanced perihilacholangiocarcinoma and GBC. This study aims to evaluate the efficacy and safety of camrelizumab in combination with HAIC-FO as conversion therapy in pts with initially unresectable advanced eCCA and GBC.
Methods
This ongoing phase II study enrolled pts with pathologically confirmed initially unresectable advanced eCCA or GBC to receive intravenous camrelizumab (200 mg, day 1, q2w) plus HAIC with oxaliplatin (40 mg/m2 for 2 h, days 1-3, q4w) and 5-fluorouracil (800 mg/m2 for 22 h, days 1-3, q4w). Treatment was continued until potential resectability could be achieved, disease progression, intolerable toxicity, or withdrawal of consent. The primary endpoint was ORR per RECIST v1.1.The secondary endpoint was organ-specific ORR and safety.
Results
Between June 15, 2021 and April 15, 2024, 42 pts were enrolled and treated. Of these, 34 pts completed at least 4 cycles of conversion therapy and 7 pts still under treatment. The median follow-up time was 12.8 months. The ORR was 47.0% and the disease control rate was 61.8%. 14 pts underwent surgery after successful conversion therapy. The conversion rate was 41.2% and the R0 resection rate was 92.8%. 5(11.9%) of 42 pts had treatment-related adverse event (TRAEs) that were Grade 3 or 4. No Grade 3 or 4 TRAEs occurred after surgery. Table: 51P
Baseline characteristic, response | |
Median age (range), y | 64 (35-75) |
Male/Female | 19/23 |
eCCA/GBC | 29/13 |
Remote metastasis exists,n (%) | 10 (23.8%) |
ORR/DCR, % | 47.0% / 61.8% |
Organ-specific ORR, % | 64.7% |
6-m PFS,% | 58.8% |
6-m OS,% | 91.2% |
Conclusions
These promising preliminary results may suggest camrelizumab in combination with HAIC-FO as an effective therapeutic regimen for initially unresectable advanced eCCA and GBC.
Clinical trial identification
ChiCTR2100044629.
Editorial acknowledgement
Legal entity responsible for the study
W. Zhai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1998P - Preliminary results from a phase I study of T3011, an oncolytic HSV expressing IL-12 and anti-PD-1 antibody, for BCG-failure non-muscle-invasive bladder cancer (NMIBC)
Presenter: Dingwei Ye
Session: Poster session 13
1999P - Expression heterogeneity of ADC-related targets between primary tumors and metastatic lymph nodes in advanced urothelial cancers
Presenter: Xingliang Tan
Session: Poster session 13
2001P - Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study
Presenter: Florence Joly Lobbedez
Session: Poster session 13
2002P - Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study
Presenter: Luzhe Yan
Session: Poster session 13
2003P - Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
Presenter: Michal Sternschuss
Session: Poster session 13
2004P - The combination of high levels of serum cytokeratin fragment 21-1 and VI-RADS≧4 has diagnostic and prognostic value in high-stage bladder cancer
Presenter: Shunsuke Ikuma
Session: Poster session 13
2005P - Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma
Presenter: Alvaro Pinto Marin
Session: Poster session 13
2006P - Prognostic factors in metastatic urothelial cancer (mUC): Developing an accessible model for predicting patient survival
Presenter: Sevinc Balli
Session: Poster session 13
2007P - Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials
Presenter: Dag Rune Stormoen
Session: Poster session 13